Anti-Mouse TIM-3 (Clone B8.2C12) – Purified in vivo GOLD™ Functional Grade
Anti-Mouse TIM-3 (Clone B8.2C12) – Purified in vivo GOLD™ Functional Grade
Product No.: T751
- -
- -
Clone B8.2C12 Target Tim-3 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody
Alternate Names HAVCR2 Isotype Rat IgG1 κ Applications FA , FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen Mouse TIM-3 protein Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? FA, FC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity B8.2C12 activity is directed against mouse TIM-3 (CD366).
Background TIM-3 is a member of the T cell immunoglobulin mucin gene family and encodes a type I
membrane protein consisting of an immunoglobulin variable-region-like domain, a mucin-like
domain, and a tyrosine phosphorylation motif1. TIM-3 functions as an important immune checkpoint receptor that helps regulate dendritic cell function2, T helper type I expansion, and induction of peripheral tolerance3. TIM-3 interacts with GAL-9, PtdSer, HMGB1 and CEACAM1 to activate biochemical pathways such as immune tolerance, T cell depletion, NF-κB signaling, and IL-2 secretion4. Additionally, TIM-3 expression correlates with terminal differentiation and exhaustion in tumors as well as chronic infection3. Due to its dysregulation in different types of cancer, TIM-3 blockade is being investigated as an anti-tumor immunotherapy2,4. TIM-3 also has potential as a prognostic marker in solid tumors4. B8.2C12 was generated by immunizing Lewis and Lou/M female rats (Harlan Sprague-Dawley) with Th1 polarized T cell clones and/or lines, including Th1-specific clone AE7 and in vitro differentiated Th1 cell lines derived from 5B6 and DO11.10 T cell receptor transgenic mice1. Spleen cells were fused with myeloma cells and a large panel of monoclonal antibodies was screened on Th1 and Th2 cells by flow cytometry. B8.2C12 selectively stained Th1 cells. Gene expression cloning was then used to identify a complementary DNA, which was TIM-3. Antigen Distribution TIM-3 (CD366) is expressed on interferon-γ producing T cells, dendritic
cells, cytotoxic lymphocytes, exhausted T cells, natural killer cells, Th17, and myeloid cells.
TIM-3 is also expressed on CD8 + T cells in the tumor microenvironment as well as intratumoral
macrophages and monocytes. TIM-3 is expressed by T helper 1 cells after several rounds of
polarization in vitro. TIM-3 is not expressed by naïve T cells.
Ligand/Receptor Expressed on activated Th1 lymphocytes, CD11b+ macrophages, and dendritic cells. NCBI Gene Bank ID UniProt.org Research Area Cell Biology . Immunology . Immune Checkpoint References & Citations1 Monney L, Sabatos CA, Gaglia JL, et al. Nature. 415(6871):536-541. 2002. 2 Dixon KO, Tabaka M, Schramm MA, et al. Nature. 595(7865):101-106. 2021. 3 Sabatos CA, Chakravarti S, Cha E, et al. Nat Immunol. 4(11):1102-1110. 2003. 4 Sauer N, Janicka N, Szlasa W, et al. Cancer Immunol Immunother. 72(11):3405-3425. 2023. 5 del Rio ML, Cote-Sierra J, Rodriguez-Barbosa JI. Transpl Int. 24(5):501-513. 2011. 6 Cong J, Wang X, Zheng X, et al. Cell Metab. 28(2):243-255.e5. 2018. 7 Chen L, Yang QC, Li YC, et al. Cancer Immunol Res. 8(2):179-191. 2020. 8 Taniguchi H, Caeser R, Chavan SS, et al. Cell Rep. 39(7):110814. 2022. 9 Guo J, De May H, Franco S, et al. Nat Biomed Eng. 6(1):19-31. 2022. Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
---|---|
T751 | |
T756 | |
T757 | |
T758 | |
T752 |
